Aldehyde Dehydrogenases (ALDHs) belong to a family of enzymes that play a key role in the metabolism of endogenous and exogenous aldehydes. This group of intracellular enzymes plays a pivotal role in embryogenesis and cell differentiation as well as in cancer progression by mediating retinoic acid signalling. Their functional activity also extends to cellular redox homeostasis via detoxification of reactive aldehydes derived from lipid peroxidation and other metabolic processes thus, playing a major cytoprotective role in cells.


Read more



ABD-3001 is a suicidal inhibitor of ALDH1 and 3. It blocks the enzyme activity irreversibly causing rapid accumulation of reactive aldehydes in tumour cells, beyond critical threshold. The accumulated aldehydes, notably HNE and MDA form genotoxic adducts with protein and DNA affecting the oncogenic signalling pathways that participate in cell proliferation.


Read more

Our vision

Advanced Biodesign

Based on our expertise in cancer metabolism and know-how in specific cell death called “apoptosis”, we will develop a new way to treat cancer to overcome actual stratification of cancer to bring new hope for patient.  By focusing on rare or bad-prognostic cancer, Advanced BioDesign offer innovative therapy to target markets with high unmet medical needs in cancer.  


Advanced BioDesign and Luxembourg Institute of Health (LIH) join forces to explore new therapeutic strategies for overcoming tumor resistance

Lyon, France, and Luxembourg, July 1, 2020 – Advanced BioDesign, a French biotechnology company specializing in the development of innovative therapies for resistant forms of cancer, and the Luxembourg Institute of Health (LIH), a public biomedical research institute, announce today a partnership to embark on a collaborative research program.

Read more
Advanced BioDesign publishes its study in Non-Smal Cell Lung Cancer (NSCLC) in Oncogene

Study shows for first time benefit of its active compound DIMATE in overcoming drug resistance in NSCLC Lyon, France, May 12, 2020 – Advanced BioDesign, dedicated to developing novel therapies against resistant cancers, today announces promising results using its dual inhibitor DIMATE against an original therapeutic target, the ALDH enzymes family, in pulmonary cancer. The results, recently published in Oncogene, demonstrate that in lung cancer xenografts with high to moderate cisplatin resistance, a combination treatment with DIMATE promotes strong synergistic responses with tumour regression.

Read more